{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":6,"sponsored":0,"items":[{"id":"n_swayslxky3bpmoey3uwq","seq":1723586,"kind":"article","title":"Adults Newly Facing Leukemia Treatment Gain Another Pill Option as FDA Clears Jaypirca for Untreated CLL","url":"https://www.medicaldaily.com/fda-approves-jaypirca-untreated-cll-17p-deletion-479508","summary":"FDA approved Lilly's Jaypirca as a first treatment for adults with CLL or SLL without 17p deletion. Here are the trial results, side effects, and costs.","published":"2026-10-04T20:40:33Z","seen":"2026-10-04T21:12:31Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q1088156","name":"chronic lymphocytic leukemia","type":"other"}],"story":"st_swayslxky3bpmoey3uwq","category":"health","category_p":0.89,"sentiment":"positive","tone":0.37,"political":0.08},{"id":"n_zeocoptiqmvsi7kbx72q","seq":1431947,"kind":"article","title":"Jaypirca approval expanded to include treatment-naive CLL, small lymphocytic lymphoma","url":"https://www.healio.com/news/hematology-oncology/20261002/jaypirca-approval-expanded-to-include-treatmentnaive-cll-small-lymphocytic-lymphoma","summary":"The FDA expanded the approval of pirtobrutinib to include initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. Pirtobrutinib (Jaypirca, Eli Lilly & Co.) — a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor — already had been approved for patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) who already received a BTK inhibitor. It also is approved for certain patients…","published":"2026-10-02T20:59:07Z","seen":"2026-10-02T21:20:29Z","lang":"en","source":{"id":"kite-healio-com-23151b","name":"healio.com","domain":"healio.com"},"via":"kite-healio-com-23151b","topics":["medicine"],"authors":["Mark Leiser"],"entities":[{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q1088156","name":"chronic lymphocytic leukemia","type":"other"}],"mentions":2,"story":"st_zeocoptiqmvsi7kbx72q","category":"health","category_p":0.71,"sentiment":"neutral","tone":0.32,"political":0.1},{"id":"n_oevfd6cb7dkjynprtztq","seq":1459198,"kind":"article","title":"FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL","url":"https://www.pharmacytimes.com/view/fda-approves-pirtobrutinib-for-previously-untreated-cll-sll","published":"2026-10-02T20:55:00Z","seen":"2026-10-03T01:28:11Z","lang":"en","source":{"id":"pharmacytimes.com","name":"pharmacytimes.com","domain":"pharmacytimes.com","outlet":{"wikidata":"Q27712672","name":"Pharmacy times","type":"website","designations":["scientific journal","website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q18557229","name":"chronic lymphocytic leukemia and small lymphocytic lymphoma","type":"other"}],"story":"st_ekxsvf5vhi4tjqzed5ta","category":"health","category_p":0.59,"sentiment":"neutral","tone":-0.17,"political":0.15},{"id":"n_hf3mdogwmaxv4iik4weq","seq":1428770,"kind":"article","title":"FDA Approves Jaypirca as First-Line Treatment for CLL and SLL","url":"https://www.curetoday.com/view/fda-approves-jaypirca-as-first-line-treatment-for-cll-and-sll","published":"2026-10-02T19:51:00Z","seen":"2026-10-02T21:09:44Z","lang":"en","source":{"id":"curetoday.com","name":"curetoday.com","domain":"curetoday.com","outlet":{"wikidata":"Q5014714","name":"CURE","type":"magazine","designations":["magazine","website"]}},"via":"gdelt-gkg-english","topics":["education","economy","health"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q1088156","name":"chronic lymphocytic leukemia","type":"other"},{"id":"Q107969614","name":"SLL","type":"other"}],"story":"st_hf3mdogwmaxv4iik4weq","category":"health","category_p":0.8,"sentiment":"positive","tone":-0.34,"political":0.12},{"id":"n_ep77polfk6bbuteyhswa","seq":1419182,"kind":"article","title":"Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL","url":"http://www.prnewswire.com/news-releases/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-btk-inhibitor-receives-expanded-indication-from-us-fda-for-certain-patients-with-previously-untreated-cllsll-302897416.html","published":"2026-10-02T19:30:00Z","seen":"2026-10-02T19:47:13Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","health","science","education"],"authors":["Eli Lilly","Company"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q18557229","name":"chronic lymphocytic leukemia and small lymphocytic lymphoma","type":"other"}],"story":"st_ep77polfk6bbuteyhswa","category":"health","category_p":0.67,"sentiment":"neutral","tone":-0.48,"political":0.13},{"id":"n_aygcky4snstfjhyrakdq","seq":408616,"kind":"article","title":"Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL","url":"https://www.rttnews.com/3694273/innovent-s-jaypirca-gets-expanded-nmpa-approval-for-cll-sll.aspx","published":"2026-09-28T10:39:00Z","seen":"2026-09-28T11:11:39Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"entities":[{"id":"Q30296199","name":"Innovent","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q17091299","name":"National Music Publishers' Association","type":"org"},{"id":"Q18557229","name":"chronic lymphocytic leukemia and small lymphocytic lymphoma","type":"other"}],"story":"st_aygcky4snstfjhyrakdq","category":"science-technology","category_p":0.44,"category2":"economy-business","sentiment":"positive","tone":0.21,"political":0.05}]}